2019 Press Releases

Keyword Search
2019 | 2018 | 2017 | 2016 | 2015
04/16/19AveXis data reinforce effectiveness of Zolgensma® in treating spinal muscular atrophy (SMA) Type 1
  Ph 3 STR1VE data show prolonged event-free survival, early and rapid increases in CHOP-INTEND and significant milestone achievement in SMA Type 1, consistent with START trial  First-in-human biodistribution data show transduction in intended CNS targets and widespread SMN expression comparable to tissue from unaffected control   More than 150 patients treated with Zolgensma, only 5% of screened patients up to 5 years old excluded due to AAV9 antibody titers greater than 1:50Base... 
 Printer Friendly Version
04/01/19AveXis expands world-leading gene therapy manufacturing capacity with purchase of advanced biologics therapy manufacturing campus in Longmont, Colorado
Facility to become the largest of four state-of-the-art sites involved in manufacturing of AveXis gene therapies for pipeline of rare genetic diseases including spinal muscular atrophyAveXis plans to offer positions to all approximately 150 employees previously employed at the site, and to announce further expansion of new jobs in the near termInvestment in the Longmont campus adds to existing $115 million investment in Durham facility, leading to creation of more than 1,000 US-based, high-tech,... 
 Printer Friendly Version

© AveXis, Inc. All Rights Reserved.